Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
10
2021
revised:
01
12
2021
accepted:
24
12
2021
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Previous studies on the effects of resveratrol on metabolic indicators reported contradictory findings, and these indicators have not been frequently studied in patients with type 2 diabetes. In this study, we aimed to examine the effects of resveratrol on metabolic indicators in a specific group of people with type 2 diabetes using the most recent literature. We used RevMan 5.4 and Stata 14.0 software to identify randomized controlled studies on the impact of resveratrol on metabolic indicators in patients with type 2 diabetes using relevant search terms and keywords such as "resveratrol" and "type 2 diabetes" in the China National Knowledge Infrastructure, PubMed, Cochrane, and Embase. Data were expressed as the weighted mean difference (WMD) and 95% confidence interval (CI). This meta-analysis included 19 studies involving 1151 patients with type 2 diabetes, including 584 patients treated with resveratrol and 567 patients who received placebo. Compared with the control data, large doses of resveratrol (≥1000 mg) reduced fasting blood glucose levels (WMD: -18.76 mg/dL, 95% CI: -23.43, -14.09; This systematic review and meta-analysis updated the most recent literature and provided new evidence, proving that resveratrol treatment can reduce systolic blood pressure and diastolic blood pressure. High-dose resveratrol can reduce fasting blood glucose in patients with type 2 diabetes, although it has no effect on waist circumference, triglyceride, and high-density lipoprotein cholesterol.
Sections du résumé
Background and Aims
UNASSIGNED
Previous studies on the effects of resveratrol on metabolic indicators reported contradictory findings, and these indicators have not been frequently studied in patients with type 2 diabetes. In this study, we aimed to examine the effects of resveratrol on metabolic indicators in a specific group of people with type 2 diabetes using the most recent literature.
Methods
UNASSIGNED
We used RevMan 5.4 and Stata 14.0 software to identify randomized controlled studies on the impact of resveratrol on metabolic indicators in patients with type 2 diabetes using relevant search terms and keywords such as "resveratrol" and "type 2 diabetes" in the China National Knowledge Infrastructure, PubMed, Cochrane, and Embase. Data were expressed as the weighted mean difference (WMD) and 95% confidence interval (CI).
Results
UNASSIGNED
This meta-analysis included 19 studies involving 1151 patients with type 2 diabetes, including 584 patients treated with resveratrol and 567 patients who received placebo. Compared with the control data, large doses of resveratrol (≥1000 mg) reduced fasting blood glucose levels (WMD: -18.76 mg/dL, 95% CI: -23.43, -14.09;
Conclusion
UNASSIGNED
This systematic review and meta-analysis updated the most recent literature and provided new evidence, proving that resveratrol treatment can reduce systolic blood pressure and diastolic blood pressure. High-dose resveratrol can reduce fasting blood glucose in patients with type 2 diabetes, although it has no effect on waist circumference, triglyceride, and high-density lipoprotein cholesterol.
Identifiants
pubmed: 35685602
doi: 10.1155/2022/9734738
pmc: PMC9158797
doi:
Substances chimiques
Blood Glucose
0
Cholesterol, HDL
0
Triglycerides
0
Resveratrol
Q369O8926L
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9734738Informations de copyright
Copyright © 2022 Wei Gu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest associated with this study.
Références
Diabetes Technol Ther. 2015 Jan;17(1):35-42
pubmed: 25375397
Am J Clin Nutr. 2016 Jan;103(1):66-70
pubmed: 26607942
Nutr Res. 2018 Jun;54:40-51
pubmed: 29914666
Cochrane Database Syst Rev. 2020 Jan 17;1:CD011919
pubmed: 31978258
Eur J Clin Pharmacol. 2016 May;72(5):615-22
pubmed: 26864966
Pharmacol Res. 2016 Sep;111:896-905
pubmed: 27520400
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Acta Diabetol. 2018 Apr;55(4):341-353
pubmed: 29357033
Phytother Res. 2019 Dec;33(12):3153-3162
pubmed: 31475415
Pharmacol Res. 2017 Mar;117:166-176
pubmed: 28012964
Mol Nutr Food Res. 2015 Jan;59(1):147-59
pubmed: 25138371
J Pediatr. 2012 Jul;161(1):11-5
pubmed: 22336575
Crit Rev Food Sci Nutr. 2018;58(17):3016-3029
pubmed: 28933578
Diabetes. 2013 Oct;62(10):3500-13
pubmed: 23884882
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1031-1034
pubmed: 31336439
Int J Hypertens. 2020 Jan 21;2020:4154010
pubmed: 32099672
Med Clin (Barc). 2022 Jun 24;158(12):576-585
pubmed: 34666902
Obesity (Silver Spring). 2019 Jan;27(1):94-102
pubmed: 30569644
Int J Sport Nutr Exerc Metab. 2014 Feb;24(1):2-13
pubmed: 23918588
BMJ. 2020 Apr 28;369:m997
pubmed: 32345662
Diabetes Metab. 2019 Jan;45(1):53-59
pubmed: 29983230
Crit Rev Food Sci Nutr. 2020;60(3):375-390
pubmed: 30421960
Am J Transl Res. 2020 Jan 15;12(1):1-18
pubmed: 32051733
Diabetologia. 2017 Sep;60(9):1561-1565
pubmed: 28776085
J Nutr Biochem. 2019 Aug;70:28-37
pubmed: 31108332
Phytother Res. 2017 Jan;31(1):108-114
pubmed: 27807887
Int J Food Sci Nutr. 2020 Dec;71(8):965-978
pubmed: 32306796
Crit Rev Food Sci Nutr. 2019;59(10):1605-1618
pubmed: 29359958
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Nutr Res. 2012 Jul;32(7):537-41
pubmed: 22901562
Endocrinol Metab Clin North Am. 2021 Sep;50(3):337-355
pubmed: 34399949
Diabetes Care. 2016 Dec;39(12):2211-2217
pubmed: 27852684
Evid Based Complement Alternat Med. 2013;2013:851267
pubmed: 24073011
Int Heart J. 2017 Aug 3;58(4):577-583
pubmed: 28701674
Cardiovasc Res. 2020 Apr 1;116(5):916-930
pubmed: 31825468
Pharmacol Res. 2018 Mar;129:141-150
pubmed: 29305228
Pharmacol Res. 2013 Jun;72:69-82
pubmed: 23557933
Ann N Y Acad Sci. 2017 Sep;1403(1):27-37
pubmed: 28675763
Life Sci. 2020 Feb 1;242:117212
pubmed: 31884092
Diabetes Metab Syndr Obes. 2020 Feb 14;13:391-403
pubmed: 32104036
Diabetes Obes Metab. 2016 Aug;18(8):783-94
pubmed: 27059700
ISRN Endocrinol. 2014 Feb 20;2014:816307
pubmed: 24701359
Food Funct. 2019 Sep 1;10(9):6042-6051
pubmed: 31486447
PLoS One. 2017 Aug 17;12(8):e0183541
pubmed: 28817690